Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3825477 | 0.85 | CYP3A4 (0.50) | CYP1A2CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL12445112 | 0.85 | CYP3A4 (0.50) | CYP1A2CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL12672378 | 0.85 | CYP3A4 (0.50) | CYP1A2CYP2C19MEN1KMT2AALDH1A1 | |
| SCHEMBL11296451 | 0.82 | PTGS2 (0.50) | PTGS2CYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL27629222 | 0.80 | PTGS2 (0.48) | PTGS2CYP1A2CYP2C9CYP2C19MEN1 | |
| SCHEMBL8750479 | 0.76 | PTGS2 (0.54) | PTGS2CYP1A2ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL11758612 | 0.76 | GRIA4 (0.50) | PTGS2CYP1A2CHRNB2CHRNA4GRIA4 | |
| SCHEMBL5464381 | 0.75 | PTGS2 (0.58) | PTGS2CYP1A2ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL20833031 | 0.75 | PTGS2 (0.58) | PTGS2CYP1A2MEN1KMT2AALDH1A1 | |
| SCHEMBL40528 | 0.75 | PTGS2 (0.58) | PTGS2CYP1A2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998961-B2 | For treating conditions associated with UDP-3-O (R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | LPXN, HAX1, LCT | PTGS2 1396/4885CYP1A2 1753/4885CYP2C9 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.